Concerns over long waits for spinal surgery

Robert Jones and Agnes Hunt (RJAH) orthopaedic hospital is facing extreme backlogs for complex spinal surgery, with waits reported to exceed 300 weeks and one Powys patient waiting five years; a meeting report cited 128 breaches of the Welsh 104-week treatment standard and 71 breaches specifically affecting Powys. RJAH attributes the problem to capacity and theatre deployment constraints, while local commissioners say mutual aid and alternative English/private capacity are unavailable, creating commissioning risk and potential service reconfiguration that could affect regional NHS resource allocation and provider performance.

Analysis

Market structure: Long, systemic waits for complex spinal surgery create near-term winners among private acute-care and orthopaedic-capable providers and global orthopaedic implant makers. If English/Welsh capacity cannot absorb cases, revenue will shift to any providers with spare theatre/surgeon capacity over 6–18 months; pricing power for specialised implants (complex spinal cages, rods) can rise 5–10% regionally if utilization increases. Public hospitals and local commissioners carrying the backlog are losers: reputational, political and budgetary strain will depress capital spending flexibility.

Risk assessment: Tail risks include rapid policy action (Welsh/UK mutual-aid or emergency funding) that redirects cases back into NHS within 30–90 days, or regulatory limits on private-provider fees; either would compress upside. Hidden dependency: throughput is theatre/surgeon-limited, not implant-limited — device revenues only rise if capacity expands (hiring locum surgeons, adding theatres), so timing mismatch of 3–12 months is likely. Catalysts: government mutual-aid decisions (30–60 days), RJAH capacity rebalancing plans for 2025–26, and quarterly results from large private hospital chains.

Trade implications: Direct plays favour large-cap device names with global orthopaedic exposure and private hospital chains with spare capacity. Preferred execution is measured: buy equity or call-spread exposure with 6–12 month horizons to capture backlog migration while limiting funding risk. Avoid concentrated bets on UK NHS contractors exposed to political cost cuts; credit spreads on regional NHS trusts could widen if reputational/outlier status persists.

Contrarian angle: Consensus focuses on NHS failure; market is underpricing the option that private and cross-border solutions (England/Scotland/IE providers) will monetise the backlog — a 6–18 month window where private operators and implant vendors outperform. Reaction is underdone for global device names but possibly overdone for UK-listed small operators that lack scale; historical parallels (post-COVID elective-surgery rebound 2021–22) saw device OEMs recover within 6–12 months while small operators lagged.

Key Decisions for Investors

• Establish a 2–3% portfolio long position in Stryker (SYK) via equity or a 12-month 1x/1.5x call spread (buy ATM, sell +20% OTM) to capture potential 6–18 month uplift in complex orthopaedic implant demand; allocate smaller weight (0.5–1%) to Smith & Nephew (SN.L) for UK-exposure.
• Initiate a 1.5–2% long position in HCA Healthcare (HCA) or Ramsay Health Care (RHC.AX) via 9–12 month call spreads to play capacity migration to private hospital chains; size exposure to no more than 3% total private-hospital allocation and add if mutual-aid is denied after 60 days.
• Reduce exposure to UK NHS-focused mid-cap contractors (e.g., Serco SRP.L) by ~25% and trim regional UK healthcare REITs (Primary Health Properties PHP.L, Assura ASK.L) by 10–15% pending clarity on government funding/mutual aid over next 30–90 days; redeploy proceeds into device OEMs or global hospital chains.
• Use a 6–9 month hedged options sleeve: buy 3–6 month puts (protective) on any long UK small-cap healthcare names where >50% revenue is NHS Wales/West regions; concurrently buy calls on global device ETF/indices (IHI or XLV) with 9–12 month expiries to capture elective-surgery rebound while capping downside.